Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025
Neuphoria Therapeutics (Nasdaq: NEUP), a clinical-stage biotechnology company focused on neuropsychiatric disorder treatments, announced it will ring the Nasdaq Opening Bell on March 3rd, 2025, at the Nasdaq MarketSite in Times Square, New York City.
The ceremony will be led by President and CEO Spyros Papapetropoulos MD, PhD, accompanied by the company's board of directors, management team, and advisors. The event celebrates Neuphoria's successful redomiciliation to the US and the launch of Neuphoria Therapeutics. The live broadcast will begin at 9:15 a.m. Eastern Time.
Neuphoria Therapeutics (Nasdaq: NEUP), una società biotecnologica in fase clinica focalizzata sui trattamenti per i disturbi neuropsichiatrici, ha annunciato che suonerà la Campana di Apertura del Nasdaq il 3 marzo 2025, presso il Nasdaq MarketSite a Times Square, New York City.
La cerimonia sarà guidata dal Presidente e CEO Spyros Papapetropoulos MD, PhD, accompagnato dal consiglio di amministrazione dell'azienda, dal team di gestione e dagli advisor. L'evento celebra la riuscita redomiciliazione di Neuphoria negli Stati Uniti e il lancio di Neuphoria Therapeutics. La trasmissione in diretta inizierà alle 9:15 ora orientale.
Neuphoria Therapeutics (Nasdaq: NEUP), una compañía biotecnológica en etapa clínica centrada en tratamientos para trastornos neuropsiquiátricos, anunció que sonará la Campana de Apertura del Nasdaq el 3 de marzo de 2025, en el Nasdaq MarketSite en Times Square, Nueva York.
La ceremonia será presidida por el Presidente y CEO Spyros Papapetropoulos MD, PhD, acompañado por la junta directiva de la compañía, el equipo de gestión y asesores. El evento celebra la exitosa redomiciliación de Neuphoria a EE. UU. y el lanzamiento de Neuphoria Therapeutics. La transmisión en vivo comenzará a las 9:15 a.m. hora del Este.
Neuphoria Therapeutics (Nasdaq: NEUP), 신경정신 장애 치료에 중점을 둔 임상 단계 생명공학 회사는 2025년 3월 3일 뉴욕 타임스퀘어에 위치한 Nasdaq MarketSite에서 나스닥 개장 종을 울릴 것이라고 발표했습니다.
이 행사는 회사의 이사회, 경영진 및 자문단과 함께 Spyros Papapetropoulos MD, PhD가 주관합니다. 이 이벤트는 Neuphoria의 성공적인 미국으로의 재도메인화와 Neuphoria Therapeutics의 출범을 기념합니다. 생중계는 동부 표준시 기준 오전 9시 15분에 시작됩니다.
Neuphoria Therapeutics (Nasdaq: NEUP), une société de biotechnologie en phase clinique axée sur les traitements des troubles neuropsychiatriques, a annoncé qu'elle sonnerait la Cloche d'Ouverture du Nasdaq le 3 mars 2025, au Nasdaq MarketSite à Times Square, New York.
La cérémonie sera dirigée par le Président et CEO Spyros Papapetropoulos MD, PhD, accompagné par le conseil d'administration de l'entreprise, l'équipe de direction et les conseillers. L'événement célèbre la redomiciliation réussie de Neuphoria aux États-Unis et le lancement de Neuphoria Therapeutics. La diffusion en direct commencera à 9h15, heure de l'Est.
Neuphoria Therapeutics (Nasdaq: NEUP), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Behandlungen von neuropsychiatrischen Störungen konzentriert, gab bekannt, dass es am 3. März 2025 die Nasdaq Eröffnungsglocke läuten wird, und zwar im Nasdaq MarketSite am Times Square in New York City.
Die Zeremonie wird vom Präsidenten und CEO Spyros Papapetropoulos MD, PhD, geleitet, begleitet von dem Vorstand, dem Managementteam und Beratern des Unternehmens. Die Veranstaltung feiert die erfolgreiche Redomizilierung von Neuphoria in die USA und den Start von Neuphoria Therapeutics. Die Live-Übertragung beginnt um 9:15 Uhr Eastern Time.
- Successfully completed US redomiciliation
- None.
BURLINGTON, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (Neuphoria or Company), ”), a clinical-stage biotechnology developing impactful treatments for neuropsychiatric disorders, bringing new hope and tangible improvements to patients’ lives, announced today that it will ring the Opening Bell at the Nasdaq MarketSite in Times Square, New York City on Monday, March 3rd, 2025.
Spyros Papapetropoulos MD, PhD, President and Chief Executive Officer will be joined by Neuphoria’s board of directors, members of the management team, and advisors.
“We are honored to ring the Nasdaq Opening Bell to celebrate our successful redomiciliation to the US and the launch of Neuphoria Therapeutics Inc. We also want to recognize the efforts of our dedicated team of professionals who have worked incredibly hard to position our company for long-term success,” said Spyros Papapetropoulos MD, PhD President and CEO of Neuphoria Therapeutics Inc. “We remain deeply committed to pioneering breakthrough therapies that address the complex needs of individuals affected by neuropsychiatric disorders.”
The live broadcast of the Nasdaq Opening Bell ceremony will begin at 9.15 a.m. Eastern Time and will available at: https://www.nasdaq.com/marketsite/bell-ringing-ceremony.
FOR FURTHER INFORMATION PLEASE CONTACT:
| General Spyridon (Spyros) Papapetropoulos info@neuphoriatx.com | Investor Relations Kevin Gardner kgardner@lifesciadvisors.com | Investor Relations Chris Calabrese ccalabrese@lifesciadvisors.com |
About Neuphoria Therapeutics Inc.
Neuphoria (Nasdaq: NEUP) is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. Neuphoria is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, “as needed” treatment of social anxiety disorder (SAD) and for chronic treatment of post-traumatic stress disorder (PTSD). BNC210 is a first-of-its-kind, well-tolerated, broad spectrum anti-anxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, Neuphoria has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions. Neuphoria's pipeline also includes the α7 nicotinic acetylcholine receptor next generation and the Kv3.1/3.2 preclinical programs, both in the lead optimization development stage.
Forward -Looking Statements
Neuphoria cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “potential,” “continue” or “project” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. The forward-looking statements are based on our current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by Neuphoria that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business and other risks described in the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K filed with the SEC, and its other reports. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Neuphoria undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks, uncertainties and other factors is included in Neuphoria’s filings with the SEC, copies of which are available from the SEC’s website (www.sec.gov) and on Neuphoria’s website (www.neuphoriatx.com) under the heading “Investor Center.” All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Neuphoria expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.
FAQ
When will Neuphoria Therapeutics (NEUP) ring the Nasdaq Opening Bell?
What is Neuphoria Therapeutics (NEUP) celebrating with the Nasdaq bell ringing?
Where can investors watch Neuphoria's (NEUP) Nasdaq bell ringing ceremony?
Who will participate in Neuphoria's (NEUP) Nasdaq bell ringing ceremony?
